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Transforming growth factor-a (TGF-/3) is the prototype of a
polypeptide regulatory factor [1]. TGF-13 exists in mammals in
three isoforms, TGF-j31, 2 and 3 and acts on virtually every
mammalian cell type regulating an array of cellular functions.
TGF-/3 is multifunctional in that depending on the state or
context of the cell, TGF-/3 can either stimulate or inhibit the
same process [2]. One of the most important properties of
TGF-/3 is its widespread effects on extracellular matrix. Most
cells in the body, including glomerular mesangial cells, are
surrounded by a complex superstructure of interacting glyco-
proteins, collagens and proteoglycans called extracellular ma-
trix [3]. The glomerular basement membrane represents a
second form of specialized extracellular matrix in the glomeru-
lus. Both glomerular matrices are important in determining the
biophysical properties of permeability and filtration. All cells
possess specific matrix surface receptors through which they
adhere to the matrix [41. Cellular attachment to the matrix
allows cells to grow, divide, differentiate, secrete products,
move and form specialized tissues. TGF-f3 influences all of
these cellular functions through its known actions to: 1) stimu-
late the production of extracellular matrix molecules; 2) inhibit
enzymes that degrade matrix; and 3) increase the expression
and adhesion phenotype of matrix receptors [1]. Collectively,
TGF-f3 acts to enhance accumulation of extracellular matrix
which is highly beneficial in a process such as wound repair, but
deleterious when it occurs in the glomerulus in glomerulone-
phritis or diabetic nephropathy [51.
Recent evidence from our laboratory suggests that there are
striking similarities between the role of TGF-f3 as a master
regulator of wound repair, and the involvement of TGF-p in
experimental glomerulonephritis (Fig. 1). The result of the
action of TGF-f3 in wound repair in the skin is the formation of
a scar. In the glomerulus, the same process can lead to
sclerosis. Thus glomeruloscierosis can be viewed as the "dark
side" of TGF-j3 and wound repair. This logic suggests a dual
role for therapy. In some cases additional TGF-f3 is beneficial
(wound repair) and in others, antagonism of TGF-/3 (glomeru-
losclerosis) is required [5].
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The known actions of TGF-/3 in wound repair are depicted in
Figure 2. Most important is the recognized ability of TGF-p to
initiate and then terminate the repair process. Failure to termi-
nate the action of TGF-/3 in the glomerulus would set the stage
for progressive glomerulosclerosis. Evidence for the involve-
ment of TGF-/3 in experimental glomerulonephritis is as fol-
lows.
We chose a model of acute mesangial proliferative glomeru-
lonephritis because mesangial proliferation and matrix expan-
sion are among the most frequent changes seen in human
glomerulonephritis [61. Furthermore, expansion of the mesan-
gial matrix in human diabetic nephropathy has been shown to
be the central pathological change underlying the development
of proteinuria, hypertension and decreased filtration [7]. Ad-
ministration of anti-thymocyte serum to rats had previously
been shown to produce a dose and complement-dependent
selective injury to mesangial cells without affecting glomerular
endothelial or epithelial cells. This immunological injury would
be the equivalent of mechanical wounding in the skin. This
model is particularly powerful because nephritic glomeruli can
be acutely isolated from the kidney, placed in tissue culture,
and labeled with isotopes to measure their biosynthetic prod-
ucts [8]. In earlier studies we had shown that TGF-f3 is unique
among growth factors in stimulating cultured mesangial [9] and
glomerular epithelial cells [10] to strikingly increase the produc-
tion of two chondroitin/dermatan sulfate proteoglycans, bigly-
can and decorin. These two proteoglycans are now recognized
as markers of TGF-13 activity. In addition, TGF-/3 strongly
induced epithelial cells and normal glomeruli to produce the
major matrix glycoprotein, fibronectin.
Our results showed that by day 4 of disease there was a clear
pattern of changes indicating the strong expression of TGF-/3
within the glomeruli [8]. Biglycan and decorin production by the
nephritic glomeruli immediately increased and reached a 49-fold
peak on day 7. Following the increase in glomerular proteogly-
can production there was histological and ultrastructural evi-
dence of enhanced accumulation of mesangial matrix which
increased on day 7 and reached a peak on day 14. Due to the
lysis of a portion of the mesangial cells by the anti-thymocyte
serum, there was an initial period of glomerular hypocellularity,
but by day 4 cellularity was normal due to influx of monocytes/
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macrophages and intrinsic mesangial cell proliferation; thereaf-
ter, there was clear mesangial cell hypercellularity which, along
with the matrix accumulation, peaked on day 14, and then
decreased.
To verify the increased TGF-/3 expression in the nephritic
glomeruli, we measured TGF-f3 mRNA by Northern analysis
and TGF-/3 protein by immunofluorescence. Increased levels of
TGF-/3 transcript were found by day 4 and were elevated
fivefold on day 7 of nephritis. The amount of RNA applied to
the gel was controlled by blotting with a probe of a normal
constitutive enzyme, whose levels were found to remain con-
stant during the disease. Staining of the glomeruli with an
antibody that recognized newly synthesized TGF-/3 protein
showed that the elevated TGF-/3 message was being translated.
To show that the increased TGF-/3 protein in glomeruli was
biologically active, we used a bioassay to measure active
TGF-/3 released into medium conditioned by the nephritic
glomeruli. The results revealed that the nephritic glomeruli
were secreting significantly increased amounts of TGF-/3 by day
1 of disease, which peaked on day 7, and then began to decline.
That the biological activity in the medium represented TGF-13
was confirmed by use of an anti-TGF-J3 antibody which neu-
tralized the TGF-/3 activity in a bioassay.
Recent data from other laboratories have also supported the
central role of TGF-/3 as causing extracellular matrix accumu-
lation in tissue following injury. In a rabbit model of anti-
glomerular basement membrane glomerulonephritis, release of
active TGF-f3 from the injured glomeruli has been strongly
correlated with renal cortical collagen synthesis and the devel-
opment of fibrosis [11], Other investigators have used our
strategy of antagonizing TGF-f3 by administering anti-TGF-J3 in
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Fig. 2. TGF-/3 orchestration of the process of wound healing clockwise
from initiation to termination.
vivo. This approach has confirmed a causal role for TGF-3 in
pathological matrix accumulation by reducing scar formation in
fetal skin, in the central nervous system following wounding
and reduction of interstitial fibrosis in a model of acute lung
injury.
In new studies from our laboratory we have conducted
experiments to further explore the similarities between wound
repair and the development of glomerulosclerosis following
glomerular injury. In the model of experimental glomerulone-
phritis we have studied, one injection of anti-thymocyte serum
leads to acute mesangial proliferative glomerulonephritis, with
significant matrix expansion, and then resolution. As in other
immunologic models, a "second shot" (of anti-thymocyte se-
rum) leads to persistent proteinuria and histologic changes. This
finding suggests that the difference between acute, reversible
disease and chronic, progressive disease is quantitative. A
marker of human glomerulosclerosis is the appearance of inter-
stitial collagen (types I and III) within the glomeruli. We found
that in normal rat glomeruli interstitial collagens are not detect-
able but appear in the pathological mesangial matrix by day 7 of
disease. Thus the acute increase in mesangial matrix induced by
TGF-/3 is the likely first step leading to progressive glomerulo-
sclerosis. Wound researchers have shown that the extracellular
matrix induced by TGF-f3 contains novel matrix components
that are not present in normal tissue. Tenascin is thought
to modulate epithelial/mesenchymal cell interaction, and is
strongly expressed in healing wounds [12]. Fibronectin synthe-
sis is strongly regulated by TGF-p in many cell types. The
fibronectin induced by TGF-f3 contains unique domains that
arise by alternative splicing of mRNA [131. One isoform of
fibronectin induced by TGF-f3 is called fibronectin ED-A (extra
domain-A).
In the glomerulonephritis model we searched for the appear-
ance of tenascin and fibronectin ED-A in the pathological
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Fig. 1. Overview of similarities between scar formation and develop-
inent of glomeruloscierosis.
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Fig. 3. Micrographs showing pathologic changes in glomeruli of gb-
merubonephritic kidneys. A. The characteristic acute finding of de-
creased cellularity in mesangial areas due to cell lysis in a glomerulus
one day after injection of anti-thymocyte serum into a rat. B. From a
rat, on day 7 of disease, that received injections of control serum six
successive days, starting on the day of the anti-thymocyte injection; C.
From an animal that received rabbit anti-TGF-f3 under a similar
regimen. A striking increase in extracellular matrix is seen as the dark,
dense material filling most of the glomerulus in Panel B. Panel C shows
a clear effect of anti-TGF-/3 in preventing the increase in glomerular
extracellular matrix that typically occurs on day 7 following injection of
anti-thymocyte serum. Periodic acid-Schiff x590.
matrix. By day 7 both tenascin and fibronectin ED-A were of TGF-/3 activity. We can now show that decorin accumulates
strongly expressed in a variable pattern involving both the in the pathological matrix in parallel with tenascin and fi-
mesangial matrix and the periglomerular area around Bow- bronectin ED-A as well as conventional fibronectin and other
man's capsule. These molecules were either absent or only matrix components.
weakly present in normal rat glomeruli. We have also stated In the glomerulonephritis model, nephritic glomeruli isolated
that the induction of biglycan and decorin synthesis is a marker on day 7 of disease produced markedly elevated amounts of
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biglycan, decorin and fibronectin, Addition of the neutralizing
anti-TGF-/3 in vitro to glomerular cultures suppressed the
synthesis of proteoglycans and fibronectin by 80%. Encouraged
by these results, we conducted additional experiments in which
anti-TGF-/3 or a control antibody were injected intravenously
into rats daily following induction of glomerulonephritis [14].
The specificity of the anti-TGF-f3 was shown by demonstrating
that it neutralized the activity of purified TGF-f3 in two separate
bioassays, The therapeutic effects of anti-TGF-/3 on the glomer-
ulonephritis were assessed using histological evaluation of
extracellular matrix accumulation and the production of proteo-
glycans by the nephritic glomeruli. The results showed that
glomeruli from animals treated with anti-TGF-/3 accumulated
much less extracellular matrix than glomeruli from the control
group (Fig. 3). Proteoglycan production by the isolated ne-
phritic glomeruli was also suppressed by 60% on day 4 and 80%
on day 7 by treatment with anti-TGF-f3. Analysis showed
equally elevated TGF-p mRNA and TGF-f3 protein in both
anti-TGF-f3 treated and control rats. Thus anti-TGF-J3 did not
interfere with induction of glomerular injury. The therapeutic
effect of anti-TGF-13, therefore, is likely to be the blocking of
the strong stimulation of extracellular matrix synthesis induced
by TGF-/3. The ability of TGF-13 to suppress the expression of
proteases and stimulate the expression of protease inhibitors
may also play a role in the accumulation of extracellular matrix.
The impressive suppression of the experimental disease
achieved with anti-TGF-f3 treatment demonstrates the impor-
tance of TGF-J3 in regulating extracellular matrix production in
glomerulonephritis.
Recent work from Ruoslahti and Yamaguchi has suggested
that the proteoglycan decorin acts as an important modulator of
TGF-/3 activity [15]. As we and others have shown, TGF-/3
strongly stimulates the production of decorin which is then both
secreted and deposited into the extracellular matrix. Decorin
binds TGF-/3 through its core protein and in so doing, neutral-
izes the biological activity of TGF-/3 [16]. The inhibition of
TGF-/3 activity is possibly due to interference with binding of
TGF-3 to a receptor. Decorin in the extracellular matrix may
bind TGF-p and thus act to accumulate TGF-/3 into a storage
site within the matrix. As depicted in Figure 4, the relationship
between TGF-/3 and decorin suggests decorin is part of a
negative feed back loop that regulates TGF-p activity [15, 16].
If decorin is a natural modulator of TGF-J3 activity, then it
would be the logical choice as a TGF-/3 antagonist to use as a
to cell drug. To explore this possibility, purified bovine decorin was
prepared and isolated from articular cartilage and human
recombinant decorin (HrD) produced in Chinese hamster ovary
cells [16]. Both species of decorin neutralized the activity of
endogenous and exogenous TGF-/3 in bioassays. These results
are encouraging and we plan to conduct experiments to test the
therapeutic potential of decorin in the glomerulonephritis
model.
We can now provide an overview of the role of TGF-f3 in
experimental glomerulonephritis and wound repair, and sum-
marize the similarities in these two biological processes (Fig. 5).
Following either mechanical or immunological wounding (inju-
ry) there is release of TGF-/3 and PDGF at the site by degran-
ulating platelets. TGF-f3 is known to produce its own expres-
sion, and to influence the production of other cytokines such as
PDGF and IL-l. PDGF has recently been shown to be induced
in the experimental model and to stimulate mesangial cell
proliferation [17]. TGF-/3 is a strong chemoattractant for mono-
cytes/macrophages which immediately invade the glomerulus.
Monocytes/macrophages along with glomerular cells may then
serve to release additional amounts of TGF-/3. The dramatic
increase in fibronectin and proteoglycan production in the
nephritic glomeruli (and in wounded skin) is characteristic of
the action of TGF-/3. As proof there is appearance within the
wound and the nephritic glomeruli of decorin, tenascin and the
ED-A isoform of fibronectin that are known to be specifically
induced by TGF-/3. In the glomerulus this is followed by healing
of the mesangial matrix to its normal state and then the buildup
of pathological matrix. TGF-/3 through its influence on other
growth factors and cytokines likely determines the degree of
mesangial cell proliferation that occurs. Then the whole process
is terminated. TGF-13 gene products disappear and matrix
synthesis is decreased. Following this the pathological matrix
begins resolution. We are currently exploring in glomerulone-
phritis the contribution of the additional effects of TGF-f3 on
inhibition of proteases that degrade matrix and the ability to
increase expression of matrix receptors on the cell surface.
The causal role of TGF-J3 in the pathological accumulation of
extracellular matrix in glomerulonephritis is confirmed by the
results using anti-TGF-/3 as a therapeutic antagonist of TGF-/3
[14]. In addition to the kidney, antagonists of TGF-j3 have now
been shown to be active in vivo in the skin, central nervous
system and the lung. Surely this list will grow. Recognizing that
wound repair and glomerulonephritis have much in common
clearly provides a powerful new insight into the pathogenesis of
Fig. 4. Decorin as a modulator of TGF-13. The core protein of decorin
binds to TGF-/3 and neutralizes its biological action. The decorin-
TGF-/3 complex may also be deposited into the extracellular matrix
and/or bind to the surface of the cell.
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glomerulonephritis and glomeruloscierosis. From this new van-
tage point it is possible to visualize novel new therapies that
may prevent humans from developing glomeruloscierosis and
end-stage renal disease.
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Fig. 5. Overview of the role of TGF-13 in
Cell proliferation glomerular injury and wound repair.
